Information  X 
Enter a valid email address

Fusion Antibodies PLC Ord 4P (FAB)

Related News

20-Nov-2020 08:38 AM

Fusion Antibodies narrows loss in H1 on higher revenue

Therapeutic drug and diagnostic company Fusion Antibodies reported narrower losses in the first half of the year compared with a year earlier as higher revenue offset increased costs. For the six months ended 30 September 2020, pre-tax losses narrowed
19-Aug-2020 09:11 AM

Fusion Antibodies losses narrow as revenue rises 79%

Antibody developer Fusion Antibodies posted a full-year loss after a rise in sales was more than offset by company expenses. Pre-tax losses for the year through March amounted to £1.07m, compared to a loss of £1.50m on-year. Revenue rose 79%
06-Jul-2020 08:46 AM

Fusion Antibodies expects to report higher revenue amid 'satisfactory' order rates

Medical company Fusion Antibodies said it expected to report larger revenue to this year amid ongoing 'satisfactory' order rates during the pandemic. The company now expected to report revenues for the year to 31 March 2020 of about £3
28-Apr-2020 09:12 AM

Fusion Antibodies to raise £3m through discounted equity placing; sees results in line with ex

Antibodies drug developer Fusion Antibodies unveiled plans to raise £3m gross through a discounted equity placing to fund its existing work on the mammalian antibody library to include Covid-19, and for its existing oncology targets. The company
30-Mar-2020 02:17 PM

Fusion Antibodies experiencing 'very limited' impact from Covid-19 pandemic

Antibody engineering group Fusion Antibodies said it had experienced a 'very limited' impact on its business from the Covid-19 pandemic and was helping some companies' efforts to combat the disease. 'The company remains fully operatio
29-Jan-2020 09:41 AM

Fusion Antibodies upgrades outlook on revenue; warns on margins

Drug company Fusion Antibodies upgraded its outlook on revenue following growth across its discovery, engineering and supply businesses in the third quarter of the year. Trading in the three months through December had continued the favourable trends exp
02-Dec-2019 02:09 PM

Fusion Antibodies posts first-half loss as expenses weigh

Antibody discovery specialist Fusion Antibodies posted a first-half loss, as expenses offset a rise in revenue. Pre-tax losses for the six months through September amounted to £0.62k, compared to losses of £0.89m on-year. Revenue increased t
22-Oct-2019 01:29 PM

Fusion Antibodies revenue rises as expected in first half

Antibody supplier Fusion Antibodies said it would post a rise in first-half revenue in line with its expectations for the full year. Revenue for the six months through September had risen to £1.7m, up from £0.7m on-year. The company had &pou
02-Jul-2019 09:30 AM

Fusion Antibodies reports wider losses as competition hurts performance

Pharmaceutical company Fusion Antibodies reported wider losses as revenues fell by nearly a fifth amid a ramp up in competition during the year. For the year ended 31 March 2019, pre-tax losses widened to £1.5m from a loss of £0.7m last year
26-Nov-2018 09:36 AM

Fusion Antibodies first-half losses widen as competition, cost pressures bite

Fusion Antibodies, a pharmaceutical research organisation, said Monday first-half losses widened sharply from a year earlier as revenues more than halved. For the six months ended 30 September, losses widened to £0.89m from £0.15m a year ea
13-Aug-2018 08:59 AM

Fusion Antibodies warns on profits amid rising competition, pricing pressures

Contract research organisation Fusion Antibodies reported Monday performance for full-year 2019 would be 'significantly' behind current market expectations after reporting slower than anticipated trading to date. Trading to date for the current
05-Mar-2018 02:37 PM

Fusion Antibodies sees annual revenue missing expectations, earnings broadly in line

Fusion Antibodies said it expected to post 40% growth in revenue for the year through March, which was below market expectations. Ebitda, however, would be 'broadly' in line with expectations at 'around breakeven'. The company said i
05-Mar-2018 08:55 AM

Fusion Antibodies sees revenue growth behind market expectations, EBITDA in-line

Fusion Antibodies said it expects revenue growth below market expectations but this would have a minimal impact on adjusted EBITDA, expected to be in-line with expectations for the year ending 31 March 2018. The firm said that while trading during the se
 
Headlines
Top categories
Company finder
Forthcoming announcements

a d v e r t i s e m e n t